Organization
Providence Health/St John Cancer Institute
4 abstracts
Abstract
Polygenic risk score calibration and association with breast cancer in diverse ancestries.Org: Myriad Genetics, Inc., Vanderbilt University Medical Center, Abramson Cancer Center, University of Pennsylvania, Providence Health/St John Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.Org: H. Lee Moffitt Cancer Center and Research Institute, Onc.AI, Ohio State University Comprehensive Canvcer Hospital, University of Rochester Medical Center Department of Neurobiology and Anatomy, Earle A Chiles Research Institute,
Abstract
Improved outcomes from reflex comprehensive genomic profiling-guided precision therapeutic selection across a major US healthcare system.Org: Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Illumina, Inc., Health Research Accelerator, Providence Health/St John Cancer Institute,
Abstract
Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy.Org: Onc.AI, University of Rochester Medical Center Department of Neurobiology and Anatomy, Ohio State University Comprehensive Canvcer Hospital, City of Hope Medical Center, City of Hope National Medical Center,